When stratified by baseline viral load of either 100,000 or > 100,000 copies/mL , 5/260 ( 1.9 % ) versus 12/134 ( 9.0 % ) RPV/FTC/TDF-treated subjects and 2/250 ( 0.8 % ) versus 1/142 ( 0.7 % ) EFV/FTC/TDF-treated subjects developed resistant isolates , respectively .